These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7538285)

  • 41. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis.
    Zachariae H; Halkier-Sørensen L; Bjerring P; Heickendorff L
    Acta Derm Venereol; 1996 May; 76(3):236-8. PubMed ID: 8800308
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The safety of iloprost in systemic sclerosis in a real-life experience.
    Bellando-Randone S; Bruni C; Lepri G; Fiori G; Bartoli F; Conforti ML; Moggi-Pignone A; Guiducci S; Giuggioli D; Colaci M; Spinella A; Ferri C; Matucci-Cerinic M
    Clin Rheumatol; 2018 May; 37(5):1249-1255. PubMed ID: 29470737
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS; Gilgor RS; Allen LM; Duvic M
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
    Mittag M; Beckheinrich P; Haustein UF
    Acta Derm Venereol; 2001; 81(4):294-7. PubMed ID: 11720181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
    Cestelli V; Manfredi A; Sebastiani M; Praino E; Cannarile F; Giuggioli D; Ferri C
    Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.
    Wise RA; Wigley FM; White B; Leatherman G; Zhong J; Krasa H; Kambayashi J; Orlandi C; Czerwiec FS
    Arthritis Rheum; 2004 Dec; 50(12):3994-4001. PubMed ID: 15593189
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis.
    Rademaker M; Thomas RH; Provost G; Beacham JA; Cooke ED; Kirby JD
    Postgrad Med J; 1987 Aug; 63(742):617-20. PubMed ID: 2447572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
    Schiopu E; Hsu VM; Impens AJ; Rothman JA; McCloskey DA; Wilson JE; Phillips K; Seibold JR
    J Rheumatol; 2009 Oct; 36(10):2264-8. PubMed ID: 19755613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial.
    Muir AH; Robb R; McLaren M; Daly F; Belch JJ
    Vasc Med; 2002; 7(4):265-7. PubMed ID: 12710841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nifedipine in the treatment of Raynaud's syndrome.
    Aldoori M; Campbell WB; Dieppe PA
    Cardiovasc Res; 1986 Jun; 20(6):466-70. PubMed ID: 3536108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paradoxical Raynaud's phenomenon following iloprost infusion in a patient with systemic sclerosis.
    Bertelle D; Bertoldo E; Bixio R; Rossini M
    Scand J Rheumatol; 2023 Jan; 52(1):91-92. PubMed ID: 35723612
    [No Abstract]   [Full Text] [Related]  

  • 57. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Balbir-Gurman A; Braun-Moscovici Y; Livshitz V; Schapira D; Markovits D; Rozin A; Boikaner T; Nahir AM
    Clin Rheumatol; 2007 Sep; 26(9):1517-21. PubMed ID: 17401513
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhaled iloprost for the treatment of Raynaud's phenomenon.
    Pakozdi A; Howell K; Wilson H; Fox S; Gonzalez L; Black CM; Denton CP
    Clin Exp Rheumatol; 2008; 26(4):709. PubMed ID: 18799113
    [No Abstract]   [Full Text] [Related]  

  • 59. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
    Finch MB; Dawson J; Johnston GD
    Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases].
    García Hernández FJ; Ocaña Medina C; Mateos Romero L; Molinillo López J; Arias Zambrano A; González León R; Sánchez Román J
    Med Clin (Barc); 2004 Apr; 122(13):501-4. PubMed ID: 15104947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.